M&A Deal Summary |
|
|---|---|
| Date | 2022-03-31 |
| Target | Ivenix |
| Sector | Medical Products |
| Buyer(s) | Fresenius Kabi USA |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Medical Products |
Fresenius Kabi USA LLC is a health care company that focuses on pharmaceuticals and medical devices used to care for critically and chronically ill patients inside and outside the hospital.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Medical Products M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-04-24 |
Akorn
Lake Forest, Illinois, United States Akorn, Inc. is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States and across the globe. Akorn, Inc. was founded in 1971 and is based in Lake Forest, Illinois. |
Buy | $4.3B |
